Opinion
Video
Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
Author(s):
Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.
Video content above is prompted by the following questions:
1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study.
a. What is the background for using tocilizumab prior to administration of bispecific antibodies?
b. What methodology was used to study this cohort of patients?
c. What results were presented?
i. N=24
ii. Median follow-up: 8.1 months
iii. CRS occurred in 6 pts (25%; 2 grade 1, 4 grade 2, no grade ≥3)
iv. Reduced incidence of CRS with teclistamab vs overall MajesTEC-1 population
2. Please provide your key takeaways from this study. What are the implications of favorable safety results with the use of prophylactic tocilizumab?
3. In what patients are you currently using prophylactic tocilizumab? Who should be considered for it?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
